• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

ISPE 2024: Exploring the impact of removing race as a diagnostic factor for chronic kidney disease: Time to potassium-lowering drugs

by Truveta Research | Aug 23, 2024 | Research, Research Insights

Authors: Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
Generating comparative effectiveness insights to accelerate therapy adoption

Generating comparative effectiveness insights to accelerate therapy adoption

by Truveta staff | Feb 22, 2024 | Data, Technology

The National Academy of Medicine has estimated that less than half of all medical care in the US is supported by adequate evidence of effectiveness. The proliferation of treatment options in some disease states and the rising costs of many of those treatments have...
Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023

Beyond claims data: Truveta showcases potential of EHR data at ISPOR EU 2023

by Truveta staff | Nov 21, 2023 | Data

ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
Real-world trends in APOE genetic testing associated with lecanemab

Real-world trends in APOE genetic testing associated with lecanemab

by Truveta Research | Nov 10, 2023 | Research, Research Insights

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023. A potential side effect of the drug is brain swelling and/or small hemorrhages and is most common for people with the APOE ε4 genetic variant, therefore rates of APOE e4...
Autoimmune disease treatments: How marital status and sex impact medication adherence

Autoimmune disease treatments: How marital status and sex impact medication adherence

by Truveta Research | Nov 2, 2023 | Research, Research Insights

Adalimumab (Humira) and etanercept (Enbrel) are high-cost specialty medications used to treat a variety of autoimmune diseases. Medication adherence is often influenced by social drivers of health, so we aimed to measure adherence using the proportion of days covered...
« Older Entries

Share this


Recent posts

  • How Truveta benchmarks AI model quality for clinical concept extraction
  • Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures
  • Evaluating recent trends in early measles vaccinations in Texas

Follow Truveta


Sign up for our newsletter

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice